Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695027 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
A Phase 2 study of Primary Open Angle Glaucoma, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT05695027: Active Phase 2 study of Primary Open Angle Glaucoma, sponsored by Columbia University.
NCT05695027 is a Phase 2 study of Primary Open Angle Glaucoma that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 250 participants, below the 281-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (11% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05695027, a Phase 2 study of Primary Open Angle Glaucoma, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Primary Outcome
The primary outcome in this study are changes in visual field results based on pointwise and global metrics between intervention and placebo groups.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dietary supplements - Nicotinamide and Pyruvate
Study Locations (3)
New York
- ColumbiaDoctors Ophthalmology - 880 Third Avenue - New York
- Columbia University Irving Medical Center - 622 W 168th St - New York
California
- Stanford University Department of Ophthalmology - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What the registry record for NCT05695027 still lists
NCT05695027 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 281-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Primary Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05695027 reports a single indexed study location in New York, California.
Frequently Asked Questions
What is clinical trial NCT05695027 about?
NCT05695027 is a clinical study titled "Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study". The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enroll...
What is the current status of trial NCT05695027?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2023-03-14. Estimated completion is 2028-01.
What conditions does trial NCT05695027 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT05695027?
The interventions under investigation include: Placebo (DRUG), Dietary supplements - Nicotinamide and Pyruvate (DRUG).
Who is sponsoring clinical trial NCT05695027?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05695027 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05695027's enrollment target sits among peer trials
250 3rd of 19 higher than 17 of 19 other Primary Open Angle Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
RECRUITING · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Ahmed Glaucoma Valve Surgery With Mitomycin-C
COMPLETED · Phase 2
-
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
COMPLETED · Phase 2
-
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI